Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

PTC takes a chance on Sangamo’s Fabry disease gene therapy

Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Thursday 13 August →